A Phase 4 interventional study of Atropine Ophthalmic and MiSight 1-day disposable contact lenses in Myopia, sponsored by Ohio State University. Completed at 1 site in United States. Open to participants aged 21 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Ohio State University · Phase 4, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Myopia by Ohio State University — 2 open to participants now, 2 under way, 1 of them phase 3. Myopia · Ohio State University.
Among the 12 studies in Myopia by Ohio State University, this one is the 4th largest by enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2024, is the only one in phase 4, and was the 10th registered.
1,166 studies on the registry are indexed under Myopia; 228 are open to participants now.
Browse Myopia studies →2 of the 12 studies in Myopia by Ohio State University are open now, in 1 country. Recruiting first, the newest first:
Ohio State University · Sites in United States
Ages 18–38
Ohio State University · Sites in United States
Ages 6–11 · Healthy volunteers
By country, each count listing its studies:
Of the 124 Myopia studies recruiting now, 20 (16%) set no upper age limit and 103 (83%) stop at 75 or younger; 85 take children under 18; 53 take healthy volunteers.
This study: 21 Years to 30 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 75 is close to the median of 79 across 929 interventional studies indexed under Myopia.
Median enrollment 51 across the 10 interventional studies, 783 across the 2 observational. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
Ohio State University is the lead sponsor of 664 studies on the registry; 149 are open to participants now.
Of its 67 completed or terminated interventional studies of FDA-regulated products, 49 (73%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Myopia by Ohio State University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to study changes in eye shape of nearsighted young adults using low-dose atropine eye drops or soft multifocal contact lenses. The main questions it aims to answer are:
Participants will:
Researchers will compare young adults using low-dose atropine to those wearing soft multifocal contact lenses and to those using no intervention to see if using these interventions affects retinal shape.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants randomized to the observation arm will receive no intervention.
Participants randomized to low-dose atropine will instill one drop of 0.05% atropine in each eye at bedtime for 12 months.
Drug: Atropine Ophthalmic
Participants randomized to soft multifocal contact lenses will wear MiSight 1-day disposable contact lenses for 5-7 days per week for 12 months.
Device: MiSight 1-day disposable contact lenses
0.05% atropine ophthalmic solution
soft multifocal contact lenses
Change in ocular shape
ocular shape, as measured by the ellipsoid fit of the retina acquired by the photos taken with ocular ultrasound (ABSolu, Quantel Medical)
Time frame: baseline to 12 months
Axial elongation (or regression)
change in axial length of the eye, as measured by Lenstar 900 (Haag-Streit)
Time frame: baseline to 12 months
Change in accommodative response
change in focusing ability of the eye, as measured with near targets and the Grand Seiko WR-5100K
Time frame: baseline to 12 months
Change in refractive error
change in refractive error, as measured with the Grand Seiko WR-5100K
Time frame: baseline to 12 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Aug 2024 to primary completion in Sep 2026, 25 months.
Of 18 phase 4 interventional studies under Myopia, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 29. This study's 25 months is close to that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Jun 2026 → Sep 2026 and completion Jul 2026 → Sep 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.